Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are observing people in South Korea who have chronic heart failure with a left ventricular ejection fraction LVEF of 40% or higher and are receiving finerenone. The study aims to understand the safety and effectiveness of finerenone, a medicine that targets a receptor in the body to reduce harm to the heart, kidneys, and blood vessels. This medication is already approved and prescribed by doctors, and the study focuses on gathering data from everyday medical care without changing treatments. Participants will receive finerenone as prescribed by their doctors during their regular medical visits. The study collects data from those who are starting finerenone treatment for chronic heart failure with LVEF of 40% or greater. There are no additional tests or visits required for the study information is gathered from medical records and interviews during routine care. During the one-year period after joining the study or until participants decide to leave, researchers will monitor any side effects or health issues that may be related to finerenone. They will also track how satisfied doctors are with the treatment over time, including symptom improvement, quality of life, and overall health. Changes in finerenone dosing will be recorded as part of the evaluation of how well the medicine works.
Actively Recruiting
Researchers are observing people with hemophilia A, a genetic bleeding disorder caused by a lack of clotting factor 8 FVIII, who use the drug damoctocog alfa pegol as prescribed by their doctors. The study aims to learn more about the safety of this drug in Korean participants who have previously used other hemophilia A treatments. Hemophilia A can cause excessive bleeding after injury or surgery, and damoctocog alfa pegol replaces the missing FVIII to help prevent or treat bleeding episodes. Participants will continue their usual treatment with damoctocog alfa pegol during routine medical care, following approved product guidelines. No study drug is provided by the researchers, and no changes to healthcare are made for study purposes. Data collection occurs over about 8 months for each participant, from December 2023 to March 2026, with information gathered from health records and routine clinic visits. Participants are involved through their regular medical visits, with no extra tests or visits required for the study. Researchers will monitor and collect data on any medical problems, including various types of adverse events and reactions, during treatment. They will also track bleeding episodes and treatment use, comparing with previous FVIII products. Safety data will be collected continuously during the 36-week observational period without interfering with standard care.
Actively Recruiting
Researchers are observing men in Korea who have either non-metastatic castration-resistant prostate cancer nmCRPC or metastatic hormone-sensitive prostate cancer mHSPC. These are types of prostate cancer where nmCRPC has not spread and does not respond to lowering testosterone, while mHSPC has spread and can be treated by lowering testosterone. The study focuses on assessing the safety of the drug darolutamide in these patients, which is already approved and prescribed by doctors. Darolutamide works by blocking hormones from attaching to androgen receptors in prostate cells, which may slow cancer growth. Participants in this study are men already prescribed darolutamide by their doctors as part of routine care. The dose and treatment length are decided by the treating physician following local guidelines. The study collects data from medical records over one year, including information on adverse events and how the drug is working. This post-marketing surveillance aims to better understand darolutamides safety in Korean patients with these prostate cancer types. During the one-year participation, patients visit their doctors every 2 to 4 months as part of normal care. At these visits, scans and blood tests are done to monitor the cancer, and patients report any medications they take and adverse events experienced. Researchers track the number, severity, and outcomes of adverse events and adverse drug reactions for up to 30 days after treatment ends. They also observe measures related to cancer progression and survival during this period. The entire study will run for about six years.
Actively Recruiting
Researchers are observing people with chronic heart failure with reduced ejection fraction HFrEF, a condition where the heart pumps blood less effectively. This study focuses on patients in Korea who are prescribed vericiguat, a drug that increases the activity of an enzyme important for heart and blood circulation. The purpose is to collect real-world data on how vericiguat is used and its safety in regular medical practice. Participants receive vericiguat as prescribed by their doctors according to approved guidelines, without any intervention from the study team. Data collection includes medical records and routine practice visits. Participants are observed for up to 12 months or until death or withdrawal, whichever occurs first. The study tracks treatment patterns, including dose levels and duration of vericiguat use. During the study, researchers will monitor all adverse events, whether or not they are related to the drug. They will also collect information on serious heart-related outcomes such as death and hospital stays due to heart failure. The main outcome measures include the number of adverse events and cardiovascular events over the observation period. This approach helps understand vericiguats use and safety in everyday care over about one year.